PET and MRI guided adaptive radiotherapy: Rational, feasibility and benefit

被引：9

作者：

Thureau, S. ^{[1
]}

Briens, A. ^{[2
]}

Decazes, P. ^{[3
]}

Castelli, J. ^{[2
,4
]}

Barateau, A. ^{[2
,4
]}

Garcia, R. ^{[5
]}

Thariat, J. ^{[6
,7
,8
]}

de Crevoisier, R. ^{[2
,4
]}

机构：

[1] Univ Rouen, Ctr Henri Becquerel, Dept Radiotherapie & Phys Med, QuantIF EA 4108, F-76000 Rouen, France

[2] Ctr Eugene Marquis, Dept Radiotherapie, Rue Bataille Flandres Dunkerque,CS 44229, F-35042 Rennes, France

[3] Univ Rouen, Ctr Henri Becquerel, Dept Med Nucl, QuantIF EA 4108, Rouen, France

[4] Univ Rennes, INSERM, CLCC Eugene Marquis, LTSI UMR 1099, F-35000 Rennes, France

[5] Inst St Catherine, Serv Phys Med, F-84918 Avignon, France

[6] Ctr Francois Baclesse, Dept Radiat Oncol, F-14000 Caen, France

[7] Normandie Univ, Unicaen, IN2P3 ENSICAEN UMR6534, Lab Phys Corpusculaire, F-14000 Caen, France

[8] ARCHADE Res Community, F-14000 Caen, France

来源：

CANCER RADIOTHERAPIE | 2020年 / 24卷 / 6-7期

关键词：

PET; MRI; ART; CELL LUNG-CANCER; POSITRON-EMISSION-TOMOGRAPHY; PHASE-I TRIAL; NECK-CANCER; FDG-PET; RADIATION-THERAPY; COMPUTED-TOMOGRAPHY; CERVICAL-CANCER; TUMOR VOLUME; METABOLIC PARAMETERS;

D O I：

10.1016/j.canrad.2020.06.017

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Adaptive radiotherapy (ART) corresponds to various replanning strategies aiming to correct for anatomical variations occurring during the course of radiotherapy. The goal of the article was to report the rational, feasibility and benefit of using PET and/or MRI to guide this ART strategy in various tumor localizations. The anatomical modifications defined by scanner taking into account tumour mobility and volume variation are not always sufficient to optimise treatment. The contribution of functional imaging by PET or the precision of soft tissue by MRI makes it possible to consider optimized ART. Today, the most important data for both PET and MRI are for lung, head and neck, cervical and prostate cancers. PET and MRI guided ART appears feasible and safe, however in a very limited clinical experience. Phase I/II studies should be therefore performed, before proposing cost-effectiveness comparisons in randomized trials and before using the approach in routine practice. (C) 2020 Published by Elsevier Masson SAS on behalf of Societe francaise de radiotherapie oncologique (SFRO).

引用

页码：635 / 644

页数：10

共 101 条

[11] End-to-end empirical validation of dose accumulation in MRI-guided adaptive radiotherapy for prostate cancer using an anthropomorphic deformable pelvis phantom [J].

Bohoudi, Omar ;

Lagerwaard, Frank J. ;

Bruynzeel, Anna M. E. ;

Niebuhr, Nina, I ;

Johnen, Wibke ;

Senan, Suresh ;

Slotman, Ben J. ;

Pfaffenberger, Asja ;

Palacios, Miguel A. .

RADIOTHERAPY AND ONCOLOGY, 2019, 141 :200-207

[12] Dynamics of tumor hypoxia assessed by 18F-FAZA PET/CT in head and neck and lung cancer patients during chemoradiation: Possible implications for radiotherapy treatment planning strategies [J].

Bollineni, Vikram R. ;

Koole, Michel J. B. ;

Pruim, Jan ;

Brouwer, Charlotte L. ;

Wiegman, Erwin M. ;

Groen, Harry J. M. ;

Vlasman, Renske ;

Halmos, Gyorgy B. ;

Oosting, Sjoukje F. ;

Langendijk, Johannes A. ;

Widder, Joachim ;

Steenbakkers, Roel J. H. M. .

RADIOTHERAPY AND ONCOLOGY, 2014, 113 (02) :198-203

[13] Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study [J].

Bradley, Jeffrey D. ;

Paulus, Rebecca ;

Komaki, Ritsuko ;

Masters, Gregory ;

Blumenschein, George ;

Schild, Steven ;

Bogart, Jeffrey ;

Hu, Chen ;

Forster, Kenneth ;

Magliocco, Anthony ;

Kavadi, Vivek ;

Garces, Yolanda I. ;

Narayan, Samir ;

Iyengar, Puneeth ;

Robinson, Cliff ;

Wynn, Raymond B. ;

Koprowski, Christopher ;

Meng, Joanne ;

Beitler, Jonathan ;

Gaur, Rakesh ;

Curran, Walter, Jr. ;

Choy, Hak .

LANCET ONCOLOGY, 2015, 16 (02) :187-199

[14] Adaptive radiotherapy: Strategies and benefits depending on tumor localization [J].

Briens, A. ;

Castelli, J. ;

Barateau, A. ;

Jaksic, N. ;

Gnep, K. ;

Simon, A. ;

De Crevoisier, R. .

CANCER RADIOTHERAPIE, 2019, 23 (6-7) :592-608

[15] Areas of High 18F-FDG Uptake on Preradiotherapy PET/CT Identify Preferential Sites of Local Relapse After Chemoradiotherapy for Non-Small Cell Lung Cancer [J].

Calais, Jeremie ;

Thureau, Sebastien ;

Dubray, Bernard ;

Modzelewski, Romain ;

Thiberville, Luc ;

Gardin, Isabelle ;

Vera, Pierre .

JOURNAL OF NUCLEAR MEDICINE, 2015, 56 (02) :196-203

[16] Changes on Midchemoradiation Therapy Fluorodeoxyglucose Positron Emission Tomography for Cervical Cancer Are Associated with Prognosis [J].

Carpenter, David J. ;

Jacobs, Corbin D. ;

Wong, Terence Z. ;

Craciunescu, Oana ;

Chino, Junzo P. .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (02) :356-366

[17]

Chen AM, 2017, CLIN TRANSL ONCOL, DOI [10,10071s120434-0171704-4, DOI 10.1007/1S120434-0171704-4.]

[18] Feasibility and limitations of bulk density assignment in MRI for head and neck IMRT treatment planning [J].

Chin, Alexander L. ;

Lin, Alexander ;

Anamalayil, Shibu ;

Teo, Boon-Keng Kevin .

JOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS, 2014, 15 (05) :100-111

[19] How Accurately Can Prostate Gland Imaging Measure the Prostate Gland Volume? Results of a Systematic Review [J].

Christie, David R. H. ;

Sharpley, Christopher F. .

PROSTATE CANCER, 2019, 2019

[20] The Potential Value of MRI in External-Beam Radiotherapy for Cervical Cancer [J].

Cree, A. ;

Liysey, J. ;

Barraclough, L. ;

Dubec, M. ;

Hambrock, T. ;

Van Herk, M. ;

Choudhury, A. ;

McWilliam, A. .

CLINICAL ONCOLOGY, 2018, 30 (11) :737-750

← 1 2 3 4 5 6 7 8 9 10 →